Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NNZ 2591

Next Previous
Drug Profile

NNZ 2591

Alternative Names: ACP-2591; Cyclo-L-Glycyl-L-2-Allylproline; NNZ-2591; PMS-001

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Alkenes; Antiparkinsonians; Behavioural disorder therapies; Cyclic peptides; Neuroprotectants; Nootropics; Piperazines; Pyrazines; Pyrroles; Small molecules; Vascular disorder therapies
  • Mechanism of Action Cell death inhibitors; Neuropeptide receptor modulators; Symporter modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pitt-Hopkins syndrome; Prader-Willi syndrome; Angelman syndrome; Telomeric 22q13 Monosomy Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome; Pitt-Hopkins syndrome; Prader-Willi syndrome; Telomeric 22q13 Monosomy Syndrome
  • Phase I Fragile X syndrome; Rett syndrome

Most Recent Events

  • 09 May 2025 Ruijin Hospital plans a phase I/II trial for Dementia in China (IV) in August 2025 (NCT06946511)
  • 19 Feb 2025 NNZ 2591 receives Fast Track designation for Pitt-Hopkins syndrome [PO,Liquid] (In children, In adolescents) in USA
  • 07 Feb 2025 US FDA grants type C meeting for NNZ 2591 in Phelan-McDermid syndrome

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top